熱門資訊> 正文
强生公司获得FDA认可集成导管消融解决方案
2026-07-08 20:41
- Johnson & Johnson (JNJ) on Wednesday announced the FDA approval for a MedTech device designed to deliver both radiofrequency and pulsed field energy in a single integrated catheter for cardiac ablation procedures.
- The product, branded as the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, is intended to help electrophysiologists handle complex cases depending on the patient's anatomy, the company said.
- The catheter solution is integrated with J&J’s (JNJ) CARTO ecosystem, a three-dimensional electroanatomical mapping platform. The company expects to begin a phased launch of the DE STSF Platform in the U.S. with the first commercial procedures set to begin this summer.
- “Following a successful introduction in Europe, we’re pleased to rapidly expand access to this technology in the U.S.,” said Michael Bodner, company group chair of electrophysiology & neurovascular at J&J’s (JNJ) MedTech division.
More on Johnson & Johnson
- Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
- Johnson & Johnson: Not Every Dollar Needs To Chase The AI Boom (Upgrade)
- Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
- Most and least shorted mid- to mega-cap healthcare stocks at the end of June
- Johnson & Johnson snaps six straight sessions of gains
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
